Raphael Pharmaceutical (RAPH) Accounts Payables (2020 - 2025)

Raphael Pharmaceutical has disclosed Accounts Payables across 6 years of filings, most recently posting $506000.0 for Q4 2025.

• Accounts Payables for Q4 2025 came in at $506000.0, up 1.2% year-over-year; the trailing twelve-month figure through Dec 2025 was $506000.0 (up 1.2% YoY), and the FY2025 annual result was $506000.0, up 1.2% from the prior year.
• Accounts Payables came in at $506000.0 for Q4 2025 at Raphael Pharmaceutical, up from $475000.0 in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $537000.0 in Q3 2024 to a low of $64000.0 in Q2 2022.
• The 5-year median for Accounts Payables is $325500.0 (2021), against an average of $296833.3.
• Across the five-year window, Accounts Payables soared 2922.22% in 2021 and tumbled 73.53% in 2022, its largest moves.
• Raphael Pharmaceutical's Accounts Payables stood at $272000.0 in 2021, then sank by 73.53% to $72000.0 in 2022, then surged by 30.56% to $94000.0 in 2023, then soared by 431.91% to $500000.0 in 2024, then advanced by 1.2% to $506000.0 in 2025.
• The last three Accounts Payables figures came in at $506000.0 (Q4 2025), $475000.0 (Q3 2025), and $473000.0 (Q2 2025), per Business Quant data.